• Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Targeting healthcare disparities through the proteomics revolution (Part 2)

February 9, 2023
Tyler Ford
LinkedInTwitter

Graphic depicting how proteomics studies can make healthcare more equitable through the use of diverse data sources and a focus on the mechanisms of disease.

An opportunity to address health disparities through next generation proteomics

Bias in biological research and discovery has led to the creation of medicines and diagnostics that benefit a privileged few (see part one of this series). Recognizing healthcare disparities caused by a lack of diversity in research samples and researchers themselves, many institutes have developed processes aimed at improving representation in biological and clinical studies (See Wang et al 2022 for a salient example in genomics).  

 

These efforts should be lauded, but we in the proteomics field can make equity a priority from the start. At Nautilus, we are determined to create a proteomics platform that is developed by and ubiquitously accessible to researchers across the globe. We hope to make it clear to the users of our technology that it is critical to:
 

  • Ensure that people from underrepresented backgrounds are included in the design of proteomics studies from their inception. 
  • Ensure the results of these studies are accessible to the participants involved in them with clear explanations of what the results do and do not mean. 
  • Ensure that study participants’ biological data is protected and that participants are explicitly aware of how their data will be used. 
  • Ensure that applications resulting from proteomic studies are accessible to the participants in those studies. 
  • Create a biomedical and healthcare workforce that includes people from underrepresented backgrounds at all levels.
     

(For more on these principles, see Jooma et al 2019)
 

Addressing healthcare disparities through proteomics and the proteomics field

Next-generation proteomics technologies are poised to achieve these principles of health equity. Unlike genomics discoveries of the past, proteomics discoveries should be inherently more applicable to diverse populations because they look directly at the molecular causes of health and disease—proteins. Proteomics technologies can provide insights into cellular functions and malfunctions that drive disease across diverse populations instead of discovering mutations that may only be associated with disease in in subpopulations of people. 

 

Beyond the inherent benefits of proteomics technologies, those of us working in proteomics can grow this field with an intentional focus on diversity. At Nautilus, we understand that true innovation comes from not only diverse scientific perspectives, but also from people with diverse personal histories. We hope that the Nautilus Proteome Analysis Platform can help solve existential problems in healthcare and beyond and, to achieve this, we know our platform must be used and developed by people who approach problems from vastly different backgrounds. Our technology can only enable solutions to problems in infectious disease, food security, climate change, and more if it is developed by and accessible to people from all walks of life.
 

A personalized proteomics future with measurements specific to each and every person

We’re designing the Nautilus Proteome Analysis platform to be accessible to researchers all over the world and it is our goal to one day give all individuals access to truly personalized measurements of their own, highly diverse determinants of health. We hope that this and similar platforms will eliminate some of the disparities that have accrued through years of underrepresentation. This goal requires that we all make a clear and conscious effort to prevent the biases of the past from resurfacing in proteomics. We are committed to making more equitable, proteomics-powered future a reality for all. 

Browse by topic

  • Nautilus in the News
  • Events
  • Research and collaborations
  • Nautilus and our Platform
  • Proteomics
  • Life at Nautilus
  • Industry Interviews
SUBSCRIBE
Back To Blog

Nautilus Biotechnology

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

 

     

+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

We use cookies in order to continually improve your experience on our website. By clicking “Accept cookies” or clicking on any content on our site, you are consenting to our use of cookies as described in our Privacy Policy. You can opt-out if you wish. Accept Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT